ライフサイエンスコーパス: phosphodiesterase inhibitor

1 sence of 3-isobutyl-1-methylxanthine, a cAMP phosphodiesterase inhibitor.

2 ioned media factor, phosphodiesterase or the phosphodiesterase inhibitor.

3 36Cl- efflux in response to beta-agonist and phosphodiesterase inhibitor.

4 of treatment with milrinone, a type III cAMP phosphodiesterase inhibitor.

5 CnAbeta(-/-) mice, however, are sensitive to phosphodiesterase inhibitor.

6 ited by a cAMP antagonist and increased by a phosphodiesterase inhibitor.

7 s rolipram, a cyclic adenosine monophosphate phosphodiesterase inhibitor.

8 " theophylline, the archetypal non-selective phosphodiesterase inhibitor.

9 pretreatment with rolipram, a selective cAMP phosphodiesterase inhibitor.

10 racellular cAMP, by cAMP derivatives, and by phosphodiesterase inhibitors.

11 nd 28, analogues of recently described novel phosphodiesterase inhibitors.

12 membrane was prevented by pretreatment with phosphodiesterase inhibitors.

13 ed by intraperitoneal injection of selective phosphodiesterase inhibitors.

14 denylate cyclase activator forskolin and the phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine

15 n, the cone outer segment was exposed to the phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine

16 (dbcGMP, 300 microM) in the presence of the phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine

17 nto immature mouse oocytes maintained in the phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine

18 yclase, into the preBotC with or without the phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine

19 was inhibited by >80% in the presence of the phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine

20 (5x10(-4) mol/L) and was potentiated by the phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine

21 the cAMP agonist, 8-bromo-cAMP, or with the phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine,

22 e agents was enhanced in the presence of the phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine.

23 ovine carotid artery smooth muscles with the phosphodiesterase inhibitor, 3-isobutyl-1-methylxanthine

24 itroso-N-acetylpenicillamine (SNAP), and the phosphodiesterase inhibitor, 3-isobutyl-1-methylxanthine

25 A pilot experiment demonstrated that the phosphodiesterase inhibitor, 3-isobutylmethylxanthine (I

26 The response of T cells to the phosphodiesterase inhibitor, 4-(3'-cyclopentyloxy-4'-met

27 do)adenosine, dibutyryl cAMP, forskolin, and phosphodiesterase inhibitors all promoted deturgescence

28 vely coupled to adenylyl cyclase, and a cAMP phosphodiesterase inhibitor ameliorated the physiologica

29 Zaprinast is a well known phosphodiesterase inhibitor and lead compound for silden

30 to use in vitro assays to identify a potent phosphodiesterase inhibitor and then to investigate its

31 more traditionally used vasodilators include phosphodiesterase inhibitors and (for those with recurre

32 d in T84 cells with application of class III phosphodiesterase inhibitors and in wild-type murine int

33 growing interest in novel therapies such as phosphodiesterase inhibitors and neuropeptides.

34 The cGMP-phosphodiesterase inhibitors and YC-1 increased the prod

35 ed with the combination of oral enoximone (a phosphodiesterase inhibitor) and oral metoprolol at two

36 IgE therapy, adenosine receptor antagonists, phosphodiesterase inhibitors) and potential (chemokine r

37 rotein, cyclic nucleotide phosphodiesterase, phosphodiesterase inhibitor, and aggregation-stage adeny

38 with 8 Br-cAMP or isomethylbutyl xanthine, a phosphodiesterase inhibitor, and by stimulation of Ca2+

39 icked by an adenylyl cyclase activator and a phosphodiesterase inhibitor, and these responses can be

40 s confirmed by adenylate cyclase activators, phosphodiesterase inhibitors, and most notably by stimul

41 drenergic receptor agonists and antagonists, phosphodiesterase inhibitors, angiotensin-converting enz

42 Pretreatment with a cGMP phosphodiesterase inhibitor antagonized the anxiogenic e

43 Positive inotropes, including phosphodiesterase inhibitors, are associated with increa

44 to 51.5% over 24 h and, in the presence of a phosphodiesterase inhibitor, blunted isoproterenol-stimu

45 Increasing cellular cGMP with phosphodiesterase inhibitors, by stimulation of soluble

46 or environmental acidification, while a cGMP-phosphodiesterase inhibitor circumvents egress repressio

47 We selected the Type 4 phosphodiesterase inhibitor, CP80,633, based on its inhi

48 f cAMP, or a blockade of cAMP degradation by phosphodiesterase inhibitor decreased NLRP3 activation.

49 es induced by methylisobutylxanthine (a cAMP phosphodiesterase inhibitor), dexamethasone, and insulin

50 e attenuation of platelet aggregation by the phosphodiesterase inhibitor EHNA (a non-ABCC4 substrate)

51 s include drugs such as nitric oxide donors, phosphodiesterase inhibitors, endothelin antagonists, an

52 DGF and 3-isobutyl-1-methylxanthine (IBMX, a phosphodiesterase inhibitor) enhanced the accumulation o

53 The antidepressant drug rolipram, a type IV phosphodiesterase inhibitor, enhances IL-10 production b

54 At higher doses the phosphodiesterase inhibitor, enoximone, has been shown t

55 ation of dibutyryl cyclic AMP (5 mM) and the phosphodiesterase inhibitor IBMX (0.5 mM) prevented the

56 Application of the phosphodiesterase inhibitor IBMX increased fluorescence

57 Thus, the phosphodiesterase inhibitor IBMX promotes the actions of

58 all regions of striatum, we administered the phosphodiesterase inhibitor IBMX to animals treated with

59 -) current following a brief exposure to the phosphodiesterase inhibitor IBMX to monitor indirectly t

60 -hydrolysable cAMP analogue 8-Br-cAMP or the phosphodiesterase inhibitor IBMX, suggesting high phosph

61 y the L-type channel blocker nifedipine, the phosphodiesterase inhibitor IBMX, the adenylyl cyclase a

62 s of PKA, a permeable analog of cAMP and the phosphodiesterase inhibitor IBMX, we show that PKA activ

63 d circadian rhythms are mimicked by a potent phosphodiesterase inhibitor, IBMX (3-isobutyl-1-methylxa

64 ffect of SNAP on mIPSCs in the presence of a phosphodiesterase inhibitor, IBMX.

65 Agents such as phosphodiesterase inhibitors, immunophilin ligands, and

66 gues, endothelin-1-receptor antagonists, and phosphodiesterase inhibitors, improve clinical function

67 Given our interest in cyclic nucleotide phosphodiesterase inhibitors in chronic lymphocytic leuk

68 rgic receptor agonists and cyclic nucleotide phosphodiesterase inhibitors in heart failure have demon

69 gated the role of pulmonary vasodilators and phosphodiesterase inhibitors in selected patients receiv

70 ata indicate that the clinical evaluation of phosphodiesterase inhibitors in the treatment of patient

71 line by beta-adrenoreceptor agonists and cGI-phosphodiesterase inhibitors in transformed nasal polyp

72 Conversely, intracellular injection of a phosphodiesterase inhibitor increased MSN neuron membran

73 another cAMP analogue (8-bromo-cAMP) or the phosphodiesterase inhibitor indolidan.

74 When phosphodiesterase inhibitor is increased with time, mimi

75 Ibudilast, a nonselective phosphodiesterase inhibitor, is used clinically in Asia

76 Addition of the nonselective phosphodiesterase inhibitor, isobutyl methylxanthine (IB

77 nylate cyclase activator, forskolin, and the phosphodiesterase inhibitor isobutylmethyl xanthine (IBM

78 st differentiation and to synergize with the phosphodiesterase inhibitor isobutylmethylxanthine (IBMX

79 e transient, but in the presence of the cAMP phosphodiesterase inhibitor isobutylmethylxanthine (IBMX

80 Increasing cAMP levels using the phosphodiesterase inhibitor isobutylmethylxanthine (IBMX

81 cGMP-gated channel agonist 8-bromo-cGMP, or phosphodiesterase inhibitor isobutylmethylxanthine to mi

82 Forskolin, phosphodiesterase inhibitor isobutylmethylxanthine, and

83 rown adipogenesis in vitro in the absence of phosphodiesterase inhibitor isobutylmethylxanthine.

84 glucose concentration in the presence of the phosphodiesterase inhibitor isobutylmethylxanthine.

85 f renal cortical slices in the presence of a phosphodiesterase inhibitor isobutylmethylxantine did no

86 Incubation of IMCD cells with the phosphodiesterase inhibitors isomethylbutylxanthine or Z

87 at administration of pentoxifylline (PTX), a phosphodiesterase inhibitor known to inhibit Th1 cytokin

88 nt sensitivities to the calmodulin-dependent phosphodiesterase inhibitors, KS505a and SCH51866.

89 Sildenafil, a type 5 phosphodiesterase inhibitor, lowers pulmonary vascular r

90 The cGMP phosphodiesterase inhibitor M&B 22948 (30 microM) and 8-

91 in an excitable system and suggest that the phosphodiesterase inhibitor may be under selection becau

92 hat CGRP gene transfer alone and with a cAMP phosphodiesterase inhibitor may be useful for the treatm

93 rovide new insights into mechanisms by which phosphodiesterase inhibitors may block malaria parasite

94 eNOS, alone or in combination with a type V phosphodiesterase inhibitor, may constitute a new therap

95 ocorticoid dexamethasone (dex), insulin, the phosphodiesterase inhibitor methylisobutylxanthine (IBMX

96 in endogenous levels of cAMP induced by the phosphodiesterase inhibitor milrinone mirrored the actio

97 Phosphodiesterase inhibitors modulate several pathways c

98 Key points include phosphodiesterase inhibitors most likely confer benefit,

99 The effect of a topical phosphodiesterase inhibitor on atopic dermatitis lesiona

100 We examined the effect of BBB022, a type IV phosphodiesterase inhibitor, on blood-brain barrier (BBB

101 tion with sildenafil, a specific type 5 cGMP phosphodiesterase inhibitor, on flow-mediated dilation i

102 lyze the effect of rolipram, a cAMP-specific phosphodiesterase inhibitor, on TNF-alpha production in

103 d-type murine intestines with class I or III phosphodiesterase inhibitors or with activators of type

104 tion inducers methylisobutylxanthine (a cAMP phosphodiesterase inhibitor) or Forskolin, both of which

105 Treatment with the phosphodiesterase inhibitor papaverine led to a mass shi

106 Phosphodiesterase inhibitors (PDE-Is) have been shown to

107 Phosphodiesterase inhibitors (PDEIs), used frequently in

108 Type 5 phosphodiesterase inhibitors potentiate the ability of N

109 utyl-1-methylxanthine (IBMX), a non-specific phosphodiesterase inhibitor, potentiated the effect of S

110 enous addition of IL-12, while Ro 20-1724, a phosphodiesterase inhibitor, potentiated the effects of

111 s induce the current suppressed by AMPA, and phosphodiesterase inhibitors prevent the suppression.

112 osuppressant, rapamycin, and theophylline, a phosphodiesterase inhibitor, promote marked dephosphoryl

113 Treatment of mice with phosphodiesterase inhibitors rescued the sleep-deprivati

114 pathway by rolipram, a selective Type 4 cAMP phosphodiesterase inhibitor, reverses MK-801-induced imp

115 Subsequent addition of the phosphodiesterase inhibitor Ro 20-1724 (0.5 mM) increase

116 inhibitor MDL 12230A (20 microM), or by the phosphodiesterase inhibitor Ro 20-1724 (50 microM).

117 The phosphodiesterase inhibitor Ro 20-1724 dose-dependently

118 nic (12-15 day) exposure to the type IV cAMP phosphodiesterase inhibitor, Ro20-1724, were examined.

119 hat pharmacologic elevation of cAMP with the phosphodiesterase inhibitor Rolipram suppresses tumor ce

120 o-cAMP and potentiated by the cAMP-dependent phosphodiesterase inhibitor rolipram, suggesting that it

121 Pretreatment with the type 4 phosphodiesterase inhibitor, rolipram, abolished thapsig

122 , alone and synergistically with the type IV phosphodiesterase inhibitor, rolipram, increased neutrop

123 Infusion of the type 4 phosphodiesterase inhibitor, rolipram, prevented thapsig

124 Concentrations of a type IV-specific phosphodiesterase inhibitor, rolipram, which had no sign

125 t phenotypes, an effect mimicked by the cAMP phosphodiesterase inhibitor, rolipram.

126 diopathic PAH population, treatment with the phosphodiesterase inhibitor sildenafil was associated wi

127 ice and decreased upon administration of the phosphodiesterase inhibitor sildenafil, which augments e

128 at is enhanced by pretreatment with the cGMP phosphodiesterase inhibitor sildenafil.

129 ies evaluating anti-endothelin-1 (bosentan), phosphodiesterases inhibitors (sildenafil), and prostano

130 ayed gastric emptying can be reversed with a phosphodiesterase inhibitor, sildenafil.

131 Loss of label is suppressed by phosphodiesterase inhibitors such as ADP-ribose and p-ni

132 Phosphodiesterase inhibitors such as amrinone may be fou

133 Potent, specific phosphodiesterase inhibitors such as E4021 may prove to

134 cell permeable cGMP derivatives, or the cGMP phosphodiesterase inhibitor sulindac sulfone (exisulind,

135 Milrinone is an intravenously active phosphodiesterase inhibitor that acts rapidly and exerts

136 horylated in the presence of theophylline, a phosphodiesterase inhibitor that creates high cAMP level

137 dichotomy was recapitulated by zaprinast, a phosphodiesterase inhibitor that elevated cGMP and separ

138 and the decrease is reversed by rolipram, a phosphodiesterase inhibitor that raises cAMP and leads t

139 Cilostazol is a new phosphodiesterase inhibitor that suppresses platelet agg

140 y 36,000 compounds, we identified a class of phosphodiesterase inhibitors that suppress let-7 targets

141 In contrast, the cAMP phosphodiesterase inhibitor, theophylline, inhibited mTO

142 e inotropic response of myocardial tissue to phosphodiesterase inhibitors through a mechanism indepen

143 The addition of cGMP or phosphodiesterase inhibitors to cultures of mature gamet

144 trated the ability of selective high-potency phosphodiesterase inhibitors to reduce prostaglandin E2,

145 -[1,2,4]oxadiazolo[4,3-a]quinoxalin, and the phosphodiesterase inhibitor Viagra, which modulate NO-de

146 y Nef is inhibited by the calcium/calmodulin phosphodiesterase inhibitor W-7 but not by the protein k

147 of a membrane-permeant analog of cAMP and a phosphodiesterase inhibitor was not sufficient to induce

148 regulator of external cAMP levels, the cAMP phosphodiesterase inhibitor, we can explain the natural

149 d and decreases in PAP in response to a cAMP phosphodiesterase inhibitor were enhanced by AdRSVCGRP.

150 lo[3,4-c]pyridine series of human eosinophil phosphodiesterase inhibitors were improved by tying the

151 as well as more potent cyclic GMP-dependent phosphodiesterase inhibitors were shown to cause inhibit

152 tor agonists, dibutyryl cAMP, forskolin, and phosphodiesterase inhibitors were used to modulate physi

153 a 30 min treatment of slices with the type V phosphodiesterase inhibitor zaprinast (20 microm) plus t

154 roduced and potentiated by the cGMP-specific phosphodiesterase inhibitor zaprinast but not the inacti

155 The cGMP phosphodiesterase inhibitor zaprinast enhanced the vasod

156 he guanylate cyclase activator YC-1, and the phosphodiesterase inhibitor zaprinast greatly reduced sp

157 The specific cGMP phosphodiesterase inhibitor zaprinast reduced the freque

158 to bradykinin and the type V cGMP-selective phosphodiesterase inhibitor zaprinast were enhanced, whe

159 ave used this natural mutation, and the cGMP phosphodiesterase inhibitor zaprinast, in wild-type and

160 gondii In doing so, we took advantage of the phosphodiesterase inhibitor zaprinast, which we show act

161 sion of bradykinin and a cyclic GMP-specific phosphodiesterase inhibitor, zaprinast (20 mg/kg), resul

162 lase, and was potentiated by a cGMP-specific phosphodiesterase inhibitor, zaprinast.